Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Mar 15;203(6):663-665.
doi: 10.1164/rccm.202010-3784ED.

Rate of Decline of FEV1 as a Biomarker of Survival?

Alberto Papi  1 , Bianca Beghé  2 , Leonardo M Fabbri  1
Affiliations
Editorial

Rate of Decline of FEV1 as a Biomarker of Survival?

Alberto Papi et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Outline of the study. Participants were assigned into one of three FEV1 trajectories of interest: no chronic obstructive pulmonary disease (COPD), COPD developed through low maximally attained FEV1 trajectory, and COPD developed through normal maximally attained FEV1 trajectory based on information from the 1976–1978 or 1981–1983 examination. After the baseline 2001–2003 examination, individuals were followed for 17 years with regard to risk of severe exacerbations of COPD, repiratory disease mortality, and all-cause mortality. Reprinted by permission from Reference .
See this image and copyright information in PMC

Comment on

References

    1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977;1:1645–1648. - PMC - PubMed
    1. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;272:1497–1505. - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 [accessed 2020 Dec 10]. Available from: https://goldcopd.org/2021-gold-reports/ - PubMed
    1. Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med. 2019;7:358–364. - PubMed
    1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed